Skip to main content
Study shows positive results for Integrated Diagnostics' lung cancer test

A 685-patient, 33-site trial published in the journal CHEST found Integrated Diagnostics' Xpresys Lung 2 test, also known as XL2, can detect early-stage cancer indicators LG3BP and C163A blood plasma proteins in 8mm to 30mm lung nodules. The test, which allows protein measurement to be combined with five standard-of-care clinical factors into a single risk assessment, demonstrated an error rate of 3%, compared with the 45% misclassification of cancers in standard of care.

Full Story: